Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Dabrafenib (Primary) ; Navitoclax (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 29 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.